Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kari L Ring

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Applied Immunohistochemistry & Molecular Morphology : AIMM|February 22, 2023
PD-L1 and MHC Class I Expression in High-grade Ovarian Cancers, Including Platinum-resistant Recurrences Treated With Checkpoint Inhibitor TherapyLaurie Griesinger, Akua Nyarko-Odoom, Santos Acosta Martinez, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 13, 2017
Endometrial Cancers With Activating KRas Mutations Have Activated Estrogen Signaling and Paradoxical Response to MEK InhibitionKari L Ring, Melinda S Yates, Rosemarie Schmandt, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 25, 2026
Will they use it? Patient and provider acceptance of chatbot screening and counseling for hereditary cancer syndromes in a geographically underserved populationMadison R Coleman, Kaylee A Underkofler, Martha H Thomas, et al.
Frontiers in Oncology|May 17, 2021
Para-Aortic Nodal Radiation in the Definitive Management of Node-Positive Cervical CancerJason C Sanders, Donald A Muller, Sunil W Dutta, et al.
Frontiers in Immunology|October 5, 2018
Gene Expression Analysis Identifies Novel Targets for Cervical Cancer TherapyJason Roszik, Kari L Ring, Khalida M Wani, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 23, 2016
Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohortKari L Ring, Amanda S Bruegl, Brian A Allen, et al.
Gynecologic Oncology|June 17, 2014
Consequences of universal MSI/IHC in screening ENDOMETRIAL cancer patients for Lynch syndromeBrittany A L Batte, Amanda S Bruegl, Molly S Daniels, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|November 25, 2025
Mesonephric-like Adenocarcinoma (MLA) Diagnostic Criteria and Controversies: Perspectives and Guidance From Pathologists in the MLA ConsortiumAnne M Mills, Elizabeth D Euscher, W Glenn McCluggage, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|February 28, 2018
Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES)Anne M Mills, Lauren C Peres, Alice Meiss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2021
A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular ResponseLinda R Duska, Virginia L Filiaci, Joan L Walker, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Applied Immunohistochemistry & Molecular Morphology : AIMM|February 22, 2023
PD-L1 and MHC Class I Expression in High-grade Ovarian Cancers, Including Platinum-resistant Recurrences Treated With Checkpoint Inhibitor TherapyLaurie Griesinger, Akua Nyarko-Odoom, Santos Acosta Martinez, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 13, 2017
Endometrial Cancers With Activating KRas Mutations Have Activated Estrogen Signaling and Paradoxical Response to MEK InhibitionKari L Ring, Melinda S Yates, Rosemarie Schmandt, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 25, 2026
Will they use it? Patient and provider acceptance of chatbot screening and counseling for hereditary cancer syndromes in a geographically underserved populationMadison R Coleman, Kaylee A Underkofler, Martha H Thomas, et al.
Frontiers in Oncology|May 17, 2021
Para-Aortic Nodal Radiation in the Definitive Management of Node-Positive Cervical CancerJason C Sanders, Donald A Muller, Sunil W Dutta, et al.
Frontiers in Immunology|October 5, 2018
Gene Expression Analysis Identifies Novel Targets for Cervical Cancer TherapyJason Roszik, Kari L Ring, Khalida M Wani, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 23, 2016
Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohortKari L Ring, Amanda S Bruegl, Brian A Allen, et al.
Gynecologic Oncology|June 17, 2014
Consequences of universal MSI/IHC in screening ENDOMETRIAL cancer patients for Lynch syndromeBrittany A L Batte, Amanda S Bruegl, Molly S Daniels, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|November 25, 2025
Mesonephric-like Adenocarcinoma (MLA) Diagnostic Criteria and Controversies: Perspectives and Guidance From Pathologists in the MLA ConsortiumAnne M Mills, Elizabeth D Euscher, W Glenn McCluggage, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|February 28, 2018
Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES)Anne M Mills, Lauren C Peres, Alice Meiss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2021
A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular ResponseLinda R Duska, Virginia L Filiaci, Joan L Walker, et al.
Pageof 6